ArticleFrontiers in oncology2026
Single-cell-derived ferroptosis signature predicts prognosis and therapy response in esophageal squamous cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. Ferroptosis, a regulated form of cell death characterized by iron-dependent lipid peroxidation, plays a crucial role in tumor progression and immune regulation. Methods: We integrated single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic data to identify ferroptosis-active cellular subpopulations within the ESCC tumor microenvironment. A ferroptosis-related prognostic model was constructed using LASSO-Cox regression and validated across independent cohorts from TCGA and GEO. Associations with immune infiltration, tumor mutation burden, therapeutic response, and drug sensitivity were explored. Furthermore, functional experiments were conducted Results: Four ferroptosis-related genes ( Conclusions: Our study presents a single-cell-resolved ferroptosis gene signature with strong prognostic and therapeutic implications for ESCC. The signature was validated in clinical tissue samples, and this model lays the foundation for ferroptosis-targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.